The approval of paltusotine (PALSONIFY™) by the FDA on September 25, 2025 not only marked a medical milestone as the first oral treatment for acromegaly, but also transformed the value of Crinetics Pharmaceuticals ($CRNX)This outcome had been anticipated on the website of Diego García del Río, where the analyst already warned that this catalyst could completely alter the company's trajectory.
Crinetics faced that moment from a privileged financial position: $1.200 billion in cash versus just $49,9 million in debt, and with market estimates projecting a revaluation of over 120%. However, the key was not only the strength of the balance sheet, but also the performance of the options marketWhere Diego García del Río detected a very marked institutional bias that offered exceptional profitability opportunities.
The bullish bias in options
In its analysis prior to the regulatory resolution, Diego García del Río He pointed out two determining factors: the open interest calls/puts ratio at 0,07, the lowest level on record, and a implied volatility at all-time highsThese data not only demonstrated the magnitude of expectations, but also defined the perfect terrain for directional strategies.
The recommendation was concrete: the Call 40 USD with maturity October 2025. After the approval, the market movement validated the thesis: Crinetics' stock rose by +27,95% intraday, while the selected option was triggered by a +446% in two days, going from $1,30 to $7,10. Those who closed their position early secured a + 230 %, and those who held until the highs captured an even greater profit.
Access the detailed report by Diego García del Río
This episode shows how a regulatory event can become a practical case of fundamental analysis combined with derivative strategiesThe full report, with a breakdown of inputs, outputs, option chains, and projected scenarios, is published on the website of Diego García del Río, where he shares research designed for investors looking to maximize every market catalyst.